Related Experiment Videos
[A clinical study on cefdinir in pediatric field]
1Department of Pediatrics, Kanto Teishin Hospital.
The Japanese Journal of Antibiotics
|October 1, 1991
Summary
Cefdinir (CFDN) demonstrated favorable pharmacokinetics and clinical efficacy in pediatric patients with acute infectious diseases. The antibiotic was well-tolerated, with no adverse reactions reported in the study.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacology
- Clinical Microbiology
Background:
- Acute infectious diseases are common in children.
- Cefdinir is a third-generation cephalosporin antibiotic.
- Understanding cefdinir's profile in pediatric populations is crucial for effective treatment.
Purpose of the Study:
- To evaluate the pharmacokinetic parameters of cefdinir in a pediatric patient.
- To assess the clinical efficacy of cefdinir in children with various acute infectious diseases.
- To determine the safety and tolerability of cefdinir in pediatric use.
Main Methods:
- Pharmacokinetic analysis in a single pediatric subject.
- Clinical efficacy assessment in 11 children diagnosed with acute tonsillitis, scarlet fever, pharyngitis, pneumonia, otitis media, and cervical lymphadenitis.
- Adverse event monitoring throughout the study period.
Main Results:
- Pharmacokinetic parameters in the pediatric subject showed a shorter Tmax, slightly lower Cmax, and a longer plasma half-life compared to adult data.
- Excellent clinical responses were observed in 63.6% of patients, with good responses in 18.2%.
- No adverse reactions were reported during the study.
Conclusions:
- Cefdinir exhibits distinct pharmacokinetic properties in pediatric patients compared to adults.
- Cefdinir demonstrates high clinical efficacy in treating a range of acute infectious diseases in children.
- Cefdinir is safe and well-tolerated in the pediatric population studied.